Increased intraepithelial T-cells in stable COPD  by Löfdahl, Magnus J. et al.
Respiratory Medicine (2008) 102, 1812e1818ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedIncreased intraepithelial T-cells in stable COPD*Magnus J. Lo¨fdahl a,b,g, Ester Roos-Engstrand c,*,g, Jamshid Pourazar c,
Anders Bucht c,f, Barbro Dahlen a,d, Go¨ran Elmberger b,e,
Anders Blomberg c, C. Magnus Sko¨ld a,ba Department of Medicine, Division of Respiratory Medicine, Karolinska Institutet, Solna, Stockholm, Sweden
b Karolinska University Hospital, Solna, Stockholm, Sweden
c Department of Respiratory Medicine and Allergy, Umea˚ University Hospital, SE-901 85 Umea˚, Sweden
d Karolinska University Hospital Huddinge, Stockholm, Sweden
e Department of Oncology and Pathology, Karolinska Institutet, Solna, Stockholm, Sweden
f Swedish Defence Research Agency, Division of CBRN Defence and Security, Umea˚, Sweden
Received 28 January 2008; accepted 19 June 2008
Available online 15 August 2008KEYWORDS
Airway epithelium;
CXCR3;
BI;
T-lymphocytes* No author had any financial suppo
* Corresponding author. Tel.: þ46 9
E-mail addresses: magnus.lofdah
pourazar@lung.umu.se (J. Pourazar),
(G. Elmberger), anders.blomberg@lun
g Contributed equally to first author
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.06.013Summary
Background: The airway epithelium is the first line of defence in the response to inhaled
particles and irritants. Chronic obstructive pulmonary disease (COPD) is an inflammatory
disease characterised by an irreversible loss of lung function, with cigarette smoking as
a major risk factor. Here, we address intraepithelial T-cells in COPD, as these cells are
a distinct T-cell subtype thought to have important regulatory functions. We hypothe-
sised that intraepithelial T-cells play a role in the response to lung irritants and that
the T-cell populations would be altered and associated with signs of inflammation in
COPD.
Methods: Bronchoscopy with endobronchial mucosal biopsy sampling was performed in 22
patients (mean age; 57) with stable COPD (median FEV1% predicted: 51). Age- and
smoking- matched smokers (S) with normal lung function (nZ 14) and age-matched
non-smokers (NS) (nZ 15) served as controls. Airway inflammation was recorded visually
using bronchitis index (BI). Biopsy specimens were processed into glycol methacrylate
resin and inflammatory cells were stained immunohistochemically.
Results: The number of intraepithelial CD4þ T-cells were significantly higher in COPD
patients compared to smokers as well as trend towards significance in non-smokers
(pZ 0.005 and pZ 0.036, respectively), whereas intraepithelial CD8þ T-cells number
were increased in patients with COPD compared to non-smokers (pZ 0.017). Bothrt or author involvement in organisations with financial interest in the subject matter.
0 7856892; fax: þ46 90 141369.
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Intraepithelial T-cells in COPD 1813patients with COPD and smokers had a higher BI than non-smokers (p< 0.001 for both).
Conclusions: The present data suggest a role for intraepithelial CD4þ and CD8þ T-cells
in stable COPD and indicate that T-cells are of importance in the long-term inflammatory
response in COPD or, alternatively, play a regulatory role.
ª 2008 Elsevier Ltd. All rights reserved.Table 1 Characteristics and lung function data on COPD
patients, smokers with normal lung function (S) and non-
smokers (NS)
COPD
(nZ 22)
S
(nZ 14)
NS
(nZ 15)
Age
(years)
57 6 54 7 56 5
Sex
(male/female)
12/10 6/8 6/7
Tobacco
(pack-years)
34###
(23e43)
34xxx
(26e38)
0
Current
smokers (n)
18 14 0
Chronic
bronchitis (n)
10 0 0
FEV1
(% of predicted)
51***###
(47e60)
100
(94e114)
109
(105e123)
FEV1/FVC (%) 56***
###
(52e62)
80
(76e84)
84
(82e84)
Reversibility
(% of predicted FEV1)
7#
(1e8)
3
(0e5)
2
(0e3)
Data are shown as mean standard deviation for age, median
and inter-quartile range for all others.
Significant difference between groups is marked with * (COPD vs
S), # (COPD vs NS) and x (S vs NS). The considered levels of sig-
nificance were p< 0.05 (*, # or x), p< 0.01 (**, ##, xx) and
p< 0.001 (***, ###, xxx).
FEV1: forced expiratory volume in one second, measured post-
bronchodilation; and FVC: forced vital capacity.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terised by a gradual and mainly irreversible loss of lung
function. The most important risk factor for developing
COPD is tobacco smoking, which leads to an inflammatory
response in the lung.1 In some smokers, this inflammation
induces structural changes in the lung and, as a conse-
quence, the development of COPD. Previous studies have
shown an increased number of inflammatory cells, such as
neutrophils and macrophages, in the bronchial mucosa of
patients with mild to severe COPD compared to control
subjects.2 This has generated the hypothesis that COPD is
associated with an amplified inflammatory response com-
pared to smokers with normal lung function.1
Airway epithelial cells can produce mediators that
initiate and modulate the host response to inhaled irritan-
ts.3e5 This inflammatory response can be further amplified
by cells infiltrating the epithelium. Intraepithelial T-lym-
phocytes seem to be of specific interest in this context,
as they constitute a distinct T-cell subset with specific acti-
vation, regulatory capacity and subsequent capability of
adhering to the bronchial epithelium, suggesting a role in
an initial defence mechanism and T-cell cytotoxicity.6
Ligands and receptors, such as CXCR3, might also play an
important role in the inflammatory response.7 Previous
studies aiming to characterize the bronchial mucosa in
COPD have mainly focused on subepithelial T-cells, report-
ing increased numbers of T-lymphocytes in this compart-
ment in COPD.8e10 In contrast, data on the intraepithelial
T-cell population in COPD are sparse.
In the current study, we, therefore, addressed intra-
epithelial T-lymphocytes in the chronicity of COPD, since
these cells are thought to play an important role in the first
line of defence in the airways and may provoke long-term
immune responses. We hypothesised that intraepithelial T-
lymphocytes modulate the response to inhaled cigarette
smoke and contribute to the pathogenesis of COPD. In
addition, we sought to determine whether any association
between intraepithelial inflammation, lung function and
signs of bronchitis were present in COPD.
Methods
Patients and control subjects
Twenty-two COPD patients aged 39e69 years (mean age 57)
were recruited (Table 1). All patients had a post-bronchodi-
lator FEV1/FVC< 70% and FEV1< 80% of predicted, accord-
ing to GOLD criteria (www.goldcopd.org), as well as
a smoking history of more than 10 pack-years. None had
clinical or radiological signs of any other lung disease
than COPD. Age-matched smokers with normal lungfunction (nZ 14), and non-smokers (nZ 15) served as con-
trols. In addition, the control group of smokers with normal
lung function was matched regarding smoking history as-
sessed as pack-years. None of the control subjects had clin-
ical signs of any lung disease and they all had a normal
chest X-ray. No patient or control subject had a history of
allergy or asthma and in vitro screening for the presence
of specific IgE antibodies against common inhaled allergens
(Phadiatop, PharmaciaeUpjohn, Uppsala, Sweden) was
negative in all participants. All subjects were in a stable
condition (i.e., none had a respiratory tract infection
within three months prior to the study), and no participant
had received oral or inhaled corticosteroids during the
three months preceding inclusion.
Ten of the 22 COPD patients and one of the smokers with
normal lung function, met the criteria of chronic bronchitis,
defined as cough and production of mucus most days of the
months for at least three months in the previous two
years.11 Characteristics of patients with chronic bronchitis
did not differ compared to those without.
Each participant gave written informed consent and
the study was approved by the local ethics committee,
Karolinska University Hospital, Stockholm, Sweden.
1814 M.J. Lo¨fdahl et al.Pulmonary function test
All subjects performed a dynamic spirometry in a standar-
dised manner (Vitalograph, Buckingham, UK), according
to the recommendations of the American Thoracic Society.12
Both slow vital capacity and forced vital capacity were
performed before and 10 min after inhalation of two doses
of 0.5 mg terbutaline (Bricanyl Turbuhaler; AstraZeneca,
So¨derta¨lje, Sweden), and reversibility was calculated.
Bronchoscopy, bronchitis index and
bronchial biopsies
Pre-medication with morphineehyoscine (Morfin-skopola-
min, Meda, Solna, Sweden) was given intramuscularly and
lidocaine (Xylocain AstraZeneca, So¨derta¨lje, Sweden) was
applied topically whereupon bronchoscopy was performed
with a flexible fiber-optic bronchoscope (Olympus F Type
P30, Tokyo, Japan). During bronchoscopy the degree of in-
flammation was visually assessed as bronchitis index (BI).13
This was defined as the sum of scores of the visual appear-
ance of airways according to the presence or absence of ab-
normal edema, erythema, secretions and friability
(0Z normal, 3Z remarkably abnormal). Consequently,
the visual appearance of airway inflammation was assessed
in a semi-quantitative manner on a scale ranging from 0 to
12 with the investigator blinded to the subject’s status
(COPD, healthy smokers or normal control).
Biopsy specimens were taken by use of pulmonary biopsy
forceps with smooth edge jaws (Radial Edge Biopsy For-
ceps, Boston Scientific, Boston, MA). From each subject,
four to six endobronchial mucosal biopsies were taken
from the sub-segmental carinae of the upper left lobe or
the apical segment of the lower left lobe.
Processing and staining of bronchial biopsies
The mucosal biopsies were immediately fixed in ice-cold
acetone with the inclusion of the protease inhibitors
phenylmethylsulphonyl fluoride (2 mM) and iodoacetamine
(20 mM). The biopsies were subsequently processed into
glycol methacrylate (GMA) resin according to a previously
described protocol.14 The GMA blocks were stored in air-
tight containers at 20 C until the staining procedures
were initiated. In order to detect mucus-secreting cells
(goblet cells) in the epithelium, two sections from each
subject were stained with Alcian blue. Immunohistochemi-
cal staining with monoclonal antibodies (MoAbs) was per-
formed as described in detail elsewhere.15 Briefly, 2 mm
sections were treated to inhibit endogenous peroxidases
by applying a solution of 0.3% hydrogen peroxide in 0.1%
sodium azide. Additionally, non-specific antibody binding
was blocked by use of Dulbecco0s minimal essential medium
containing 10% foetal calf serum and 1% bovine serum albu-
min. Undiluted blocking medium was applied for 30 min and
then poured off, whereupon mouse MoAbs (Table 2) were
applied and incubated for 16e20 h at room temperature.
Biotinylated rabbit anti-mouse immunoglobulin F(ab0)2
(Dako, Glostrup, Denmark) was added to each section and
incubated for 2 h, and subsequently a complex of streptavi-
dinebiotinehorseradish and peroxidase (Dako) was addedfor 2 h. Aminoethyl carbazole in acetate buffer (pH 5.2)
and hydrogen peroxide were used to induce a red colour,
in this manner marking positive immunoreactions. All
sections were counterstained with Mayer’s haematoxylin.
Primary antibody was omitted on sections serving as nega-
tive controls. Two stained sections from each participant
were estimated with respect to epithelium quality, and
the best of these was used for quantifying positively stained
cells.
Quantification of staining in mucosal biopsy
specimens
The intact epithelium was defined as the area above the
basement membrane. The total length was calculated by
use of computer assisted image analysis (Qwin, Leica
Q500IW; Leica, Cambridge, UK). Quantification of positive
stained cells was performed using a light microscope. The
number of positive stained cells was expressed as cells per
millimeter of epithelium as previously described.15
Statistical analysis
Statistical comparisons between the three groups were
made using KruskaleWallis test and a p-value of less than
0.05 was considered significant. If the KruskaleWallis test
indicated significance, the ManneWhitney U-test was used
for post hoc analysis for comparison between two groups,
with corrections of p-values according to Bonferroni
(a p-value less than 0.017 was considered significant). Cor-
relations were calculated using Spearman’s rank correla-
tion test. The level of significance considered was 0.01. In
case of a statistically significant result, the probability
value (p-value) has been given.
Results
Bronchitis index
The COPD group as well as smokers with normal lung
function displayed higher (p< 0.001 for both) bronchitis
index than the non-smoker group (COPD 4, 3e6 (median
and interquartile range); smokers with normal lung function
3, 3e4; non-smokers 1, 0e2). Bronchitis index did not differ
significantly between COPD patients and smokers with nor-
mal lung function (pZ 0.06). There was no difference in
bronchitis index when comparing the COPD patients who
fulfilled the criteria for chronic bronchitis to those without.
Biopsy findings
There was no significant difference in analysed epithelial
length, expressed in mm, between the groups.16 Positive
staining for monoclonal antibodies revealed a ring-staining
pattern for CD3þ, CD4þ and CD8þ lymphocytes (Fig. 1).
The number of intraepithelial CD3þ lymphocytes mm1
epithelium in the COPD group (9.1, 0.7e27) (median,
inter-quartile range) was higher compared to the number
of intraepithelial CD3þ lymphocytes in smokers with nor-
mal lung function (1.5, 0e6.2) and to non-smokers (3.2,
0e8.3), but the difference did not reach statistical
Table 2 Monoclonal antibodies to epithelial inflammatory cells used in the present study
Antibody Marker Dilution Clone Source
Anti-CD3 T-lymphocytes CD3 1:1000 UCHT 1 DAKO, Glostrup, Denmark
Anti-CD4 T-helper cells CD4 1:15 MT310 DAKO, Glostrup, Denmark
Anti-CD8 Cytotoxic T-cells CD8 1:100 DK 25 DAKO, Glostrup, Denmark
Anti-CXCR3 Expression of interferon
inducible CXC chemokines receptor
1:150 49801 R&D, Abingdon, UK
Anti-CD68 Macrophages CD68 1:100 PG-M1 DAKO, Glostrup, Denmark
Anti-NE Neutrophil elastase 1:800 NP57 DAKO, Glostrup, Denmark
Anti-EG-2 Eosinophils ECP 1:150 EG2 PharmaciaeUpjohn Diagnostic AB, Sweden
Intraepithelial T-cells in COPD 1815significance (pZ 0.058; KruskalleWallis). The number of
intraepithelial CD4þ lymphocytes mm1 epithelium was
significantly higher in the COPD group (3.0, 0e7.1) com-
pared to smokers with normal lung function (0, 0e0.2) as
well as trend towards significance in non-smokers (0,
0e1.7) (pZ 0.005 and pZ 0.036, respectively). However,
there was no difference in the number of intraepithelial
CD4þ T-cells of COPD patients with a history of chronic
bronchitis compared to those without (pZ 0.56). The num-
ber of intraepithelial CD8þ lymphocytes mm1 epitheliumFigure 1 Representative photomicrographs showing bron-
chial epithelium of patients in the COPD group. Immunohisto-
chemical staining of bronchial biopsies for: (a) CD4þ cells
and (b) CD8þ cells.was significantly higher (pZ 0.017) in the COPD group
(7.3, 0.8e17) compared to the non-smoking controls (0,
0e6.3), without a significant difference compared to
smokers with normal lung function (1.8, 0e7.1) (Fig. 2).
Within the group of COPD patients, the majority of
patients did not exhibit cells positive for CXCR3 within the
epithelium. Notably, only the three COPD patients with the
highest numbers of intraepithelial CD4þ T-lymphocytes
(ranging from 11 to 18 CD4þ T-cells mm1 epithelium)
showed positive staining for CXCR3. No similar pattern
was present for the COPD patients with high number of
CD8þ T-cells.
Additionally, within the COPD group, the number of
intraepithelial CD4þ T-cells was positively associated with
the number of intraepithelial CD8þ T-cells; RsZ 0.85
(p< 0.001).
There was no difference in the CD4þ/CD8þ ratio
between the three groups. The number of epithelial airway
inflammatory cells such as neutrophils, macrophages,
eosinophils did not differ between the groups, neither did
mucus staining with Alcian blue (data not shown). In COPD,
no association was found between T-lymphocytes, lung
function parameters or BI.
Discussion
In this study, we demonstrate differences in intraepithelial
T-cell subsets in stable COPD patients compared to smokers
with normal lung function and non-smokers. The visual
appearance of the bronchial mucosa indicated signs of
bronchitis, assessed as BI, in the two smoke-exposed groups
compared to the non-smoking controls. However, no asso-
ciation was found between BI, lung function and the
presence of inflammatory cells in the bronchial epithelium.
We collected endobronchial mucosal specimens using
bronchoscopy in stable steroid-naı¨ve COPD patients, i.e.
the patients had no clinical history of present or recent
exacerbation. In addition, the patients were recruited to
this project solely for research purposes. They had no other
diseases than COPD and they were not investigated for any
other reasons than research. This gives an opportunity to
include an age- and smoking- matched patient and control
material, and it minimizes the risk of influence by a number
of variables such as co-morbidity, medications and exacer-
bations. By the use of bronchoscopy it is also possible to
sample endobronchial mucosal biopsies at predetermined
sites in the airways reducing the risk of sampling error.
Moreover bronchial biopsies sampled proximally through
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Figure 2 The number of T-lymphocytes mm1 epithelium in
bronchial biopsies, given for the three groups COPD, smokers
with normal lung function (S) and non-smokers (NS). Each point
depicts the result from one subject and the median of the
group is marked with a horizontal bar. Significant difference
between groups is marked with *(p< 0.017) or **(p< 0.01). Re-
sults given for: (a) CD3þ cells, (b) CD4þ cells, and (c) CD8þ
cells.
1816 M.J. Lo¨fdahl et al.the bronchoscope are suitable for the GMA embedding
technique, which enables an excellent morphology, out-
standing other immunohistochemical methods.14
The present data indicate increased CD4þ T-cells in
bronchial epithelium in COPD compared to both control
groups. In an early study by Fournier et al17 it was reported
increased numbers of intraepithelial lymphocytes in
patients with chronic bronchitis compared to smoking and
non-smoking controls. In that study, however, the degreeof airflow obstruction assessed as FEV1 was not accounted
for. Consequently, it was not clear whether the patients
had COPD or not. In the present study, COPD patients
with and without chronic bronchitis were compared and
no differences in intraepithelial CD4 numbers were found
between the two groups. Saetta et al18 found no difference
in intraepithelial T-lymphocytes when comparing patients
with chronic bronchitis to asymptomatic smokers. The
objective in the latter study was to address inflammation
in the bronchial glands, and not primarily a difference in
intraepithelial T-lymphocytes. In addition, Saetta et al
included both patients with and without concomitant
COPD. Regarding studies of populations consisting exclu-
sively of COPD patients, the total number of leukocytes
(CD45þ) have been reported to be increased in the airway
epithelium.8
Most studies in the past decade addressing airway
inflammation in COPD have focused on the submucosal
compartment, but the importance of studies examining the
airway epithelium in COPD has recently been underlined.19
This is crucial since the bronchial epithelium is the first line
of defence against inhaled particles and toxic compounds
as well as in the immune defence against microorganisms.
Furthermore, the bronchial epithelium play an important
role in the secretion of pro-inflammatory mediators and
by intraepithelial lymphocyte cellecell interactions. Apart
from the role in the defence against inhaled particles,
pollutants, viruses, bacteria and other microorganisms,
epithelial cells may also interact with inflammatory and
structural cells important in resolution after injury.
The increase in intraepithelial T-cells in COPD may have
the potential of either promoting a T-helper immune
response or exaggerating cytotoxic activity against injured
cells in the epithelium.20 The tendency towards amplified
numbers of CD8þ and CD4þ intraepithelial lymphocytes,
along with a positive association between the two sub-
types, suggest a chronic immune response involving both
these cell types in patients with stable COPD, despite no
increased numbers of clinical exacerbation increased
neutrophil numbers in the epithelium. Various triggers of
epithelial responses may induce immune activation that
would result in T-cell infiltration. It is well documented
that both bacterial21 and latent viral infection22 are com-
mon in patients with COPD. Lymphocytes situated intraepi-
thelially have features distinct from lymphocytes in the
subepithelium,6 such as long survival and elevated expres-
sion of aEb7 (CD103). This latter fact has been suggested
to imply a capacity of firm adhesion to epithelial cells,
which is required to mediate T-cell cytotoxicity.23 Thus,
the epithelial T-cell infiltration seen here may be consistent
with either a response to a latent intracellular infection or
a chronic trigger of intraepithelial lymphocytes through
injured epithelial cells. It should be considered that the in-
creased CD8þ cells may indicate a cytotoxic response
against stressed or injured epithelial cells due to long-
term exposure to cigarette smoke. Such responsiveness of
activated CD8þ cells has previously been reported to be
dependent on up-regulation of the MHC class 1-like mole-
cules MIC A and MIC B on stressed epithelial cells, and the
expression of the counter receptor NKG2D on cytotoxic
cells.24 However, it is not yet demonstrated that cigarette
smoke can induce such T-cell activation.
Intraepithelial T-cells in COPD 1817We found that the three COPD patients with the highest
number of CD4þ cells also had the highest expression of
CXCR3, which is a receptor for interferon inducible CXC
chemokines such as IP-10, MIG and I-TAC. Lung lymphocytes
in patients with COPD secrete more interferon inducible
proteins, and CXCR3 might be involved in the recruitment
of CD4þ cells to the epithelium.7,25 CXCR3 is a marker for
Th1 cells and it is suggested that Th1 lymphocytes in the
lungs of people with smoking-related damage, drive the
progression of emphysema through CXCR3 ligands. Based
on our data, it is not possible to conclude any Th1 bias of
the increased intraepithelial CD4þ population.
In the COPD patients, in contrast to the findings by
Saetta et al, who have shown increases in PMNs in the
subepithelium of COPD patients,26 no increased numbers
of intraepithelial neutrophils were found in the present
study. Neither were any signs of enhanced mucus secre-
tion, assessed as goblet cells number detected. This might
be due to the fact that the COPD patients in this study
were stable, and without any clinical signs of exacerba-
tions. The epithelial lymphocyte response in COPD might
thus be a sign of a chronic immune response, rather than
persistent inflammatory infiltrates in the bronchial
epithelium.
In conclusion, we report increased numbers of intra-
epithelial lymphocyte subsets in bronchial biopsies from
COPD patients. Based on our findings in the present report,
we suggest that intraepithelial T-lymphocytes could be of
importance in the long-term chronicity of the disease and
may play a regulatory role in the inflammatory response.
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